Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Exploratory Study of Personalized Cancer Vaccine (ABO2109) in Adjuvant Therapy of Solid Tumors

NCT07680582 is registered in ClinicalTrials.gov with Ruijin Hospital as lead sponsor.

NCT NCT07680582
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07680582 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Exploratory Study of Personalized Cancer Vaccine (ABO2109) in Adjuvant Therapy of Solid Tumors
Lead sponsor
Ruijin Hospital
Phase
Phase 1
Overall status
Recruiting
Start date
June 9, 2026
Completion date
February 9, 2031
Enrollment
60 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor